drugset
drugset / Trial / NCT03128164

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

NCT03128164 ↗

Phase 1 Completed 200 enrolled Hutchison Medipharma Limited
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).

Timeline

Start
2017-08-08
Primary completion
2023-08-02
Completion
2023-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AMDIZALISIB Small molecule 2.5 mg Oral
Subject AMDIZALISIB Small molecule 10 mg Oral

Indications

lymphoma